Business Description
BridgeBio Pharma is a drug development company focused on finding and delivering treatments for patients with inherited genetic conditions. Founded in 2015 and based in Palo Alto, California, the company has several medicines either already on the market or in late-stage clinical testing, targeting conditions that affect the heart, bones, muscles, and other systems. BridgeBio works alongside partners including Bayer, Alexion, Novartis, and Stanford University to advance its pipeline of therapies.
